Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 17/20 | 0.43 |
| ▸ | CTSL | P07711 | 12/20 | 0.41 |
| ▸ | CTSS | P25774 | 8/20 | 0.41 |
| ▸ | CTSB | P07858 | 4/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | CTSV | O60911 | 2/20 | 0.40 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.40 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4823843 | 0.94 | TAS1R3 (0.49) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL4768321 | 0.91 | CCR1 (0.42) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL4770472 | 0.89 | CTSK (0.42) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL4765600 | 0.88 | CTSK (0.54) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL4766629 | 0.87 | CTSK (0.46) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL4830428 | 0.86 | CTSK (0.46) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL4821292 | 0.86 | CTSK (0.56) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL4763062 | 0.85 | GRN (0.47) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL4762204 | 0.85 | CTSK (0.45) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL4770696 | 0.83 | CTSL (0.47) | CTSKCTSLCTSSCTSBCTSV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1320370-A4 | METHOD OF TREATMENT | SMITHKLINE BEECHAM CORP (US) | 2008-10-22 | — | — | EP | disclosed |
| EP-1320370-A1 | METHOD OF TREATMENT | SmithKline Beecham Corporation (US) | 2003-06-25 | — | — | EP | disclosed |
| WO-2002017924-A1 | METHOD OF TREATMENT | SMITHKLINE BEECHAM CORPORATION (GB) | 2002-03-07 | — | — | WO | disclosed |